Assistant Professor
BSc (Statistics), MSc (Statistics), PhD (Epidemiology)
British Columbia Centre for Excellence in HIV/AIDS
608-1081 Burrard Street
Vancouver, British Columbia V6Z 1Y6

I am an Assistant Professor at UBC since 2011 and a Research Scientist and Senior Statistician at the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) since 2006. The focus of my research career is on the epidemiology and control of the Human Immunodeficiency Virus (HIV) and, more recently, the hepatitis C virus (HCV). Based on my extensive training in statistics, epidemiology and mathematical modeling, I develop innovative models of disease progression and transmission to understand the potential impact of behavioral and health care interventions on these epidemics. Since commencing my research career, I have received numerous national/international awards, published 137 peer-reviewed papers in high-impact journals, and trained several junior researchers. I am part of numerous national/international collaborations and advisor for several national/international agencies including the World Health Organization, the International AIDS Society, the Brazilian Government, and the Chinese Center for Disease Control. Currently, I have a CIHR and a MSFHR salary awards, and I am the principal investigator on two grants and a co-investigator on eight grants.

CIHR New Investigator Award and MSFHR Scholar Award

SPPH 500 Analytic Methods in Epidemiological Research
Elective Teaching – Clinical and Population Health Research for 3rd and 4th year medical students; University of British Columbia – Faculty of Medicine – Medicine – Division of AIDS


Huiting Ma (MSc Statistics Department) – Graduated in 2015

Now accepting Master and PhD level students

Peer Reviewed Journals

For other years, you can find my publications in PUBMED by searching lima v[au] AND (HCV OR HIV)

Total Number: 137

2016 (N=9)

1. Lima VD, Hull M, McVea D, Chau W, Harrigan PR, Montaner JSG. Long-Term Effectiveness of Initiating on a Non Nucleoside Reverse Transcriptase Inhibitor- versus Ritonavir Boosted Protease Inhibitor-Based Antiretroviral Therapy: Implications for First-Line Therapy Choice in Resource-Limited Settings. J Int AIDS Soc. 2016. [accepted]
2. St-Jean M, Harrigan PR, Sereda P, Montaner JSG, Lima VD. An Assessment of the Relationship between the World Health Organization HIV Drug Resistance Early Warning Indicators and HIV Drug Resistance Acquisition. HIV Medicine. 2016. [accepted]
3. Lee GQ, Lachowski C, Cai E, Lima VD, Boum Y, Muzoora C, Mocello AR, Hunt PW, Martin JN, Bangsberg DR, Harrigan PR. Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. AIDS. 2016;30(11):1781-8.
4. Kesselring S, Cescon A, Colley G, Osborne C, Zhang W, Raboud JM, Hosein SR, Burchell AN, Cooper C, Klein MB, Loutfy M, Machouf N, Montaner J, Rachlis A, Tsoukas C, Hogg RS, Lima VD; Canadian Observational Cohort Collaboration (CANOC). Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy. HIV Med. 2016. [Epub ahead of print]
5. Cheung CC, Ding E, Sereda P, Yip B, Lourenco L, Barrios R, Montaner J, Hogg RS, Lima V, Moore DM. Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001-2012. HIV Med. 2016. [Epub ahead of print].
6. Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, Milloy MJ, Krajden M, Olmstead A, Joy JB, Marshall BD, Hayashi K, Pybus OG, Lima VD, Magiorkinis G, Montaner J, Lamoury F, Dore GJ, Wood E, Grebely J. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. J Hepatol. 2016;64(6):1247-55.
7. Rozada I, Coombs D, Lima VD. Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. J Theor Biol. 2016 Apr 21;395:31-9.
8. Lourenço L, Nohpal A, Shopin D, Colley G, Nosyk B, Montaner J, Lima VD; Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) Study Group. Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care. HIV Med. 2016;17(4):269-79.

2015 (N=12)

1. Lourenço L, Nohpal A, Shopin D, Colley G, Nosyk B, Montaner J, Lima VD; Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) Study Group. Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care. HIV Med. 2015. (In press) (Impact factor 3.5; Citations 0)
2. Lima VD, Reuter A, Harrigan PR, Lourenco L, Chau W, Hull M, Mackenzie L, Guillemi S, Hogg RS, Barrios R, Montaner JSG. Initiation of Antiretroviral Therapy at High CD4 Cell Counts Is Associated with Positive Treatment Outcomes. AIDS 2015 [accepted] (Impact factor 6.6; Citations 0)*
3. Lima VD, Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JSG, Spaulding. The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLoS One. 2015; 10(4):e0123482. (Impact factor 3.5; Citations 1)
4. Lima VD, Lourenco L, Yip B, Hogg R, Phillips P, Montaner JSG. Trends in AIDS incidence and AIDS-related mortality in British Columbia between 1981 and 2013. Lancet HIV. 2015; 2(3):e92-e97. Impact factor – too new; Citations 1)
5. Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, Burchell AN, Cooper C, Klein MB, Rourke SB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS; CANOC collaboration. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015 Jul 17;15:274. (In press) (Impact factor 2.6; Citations 0)
6. Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Krajden M, Marshall BD, Montaner J, Lima VD, Olmstead AD, Milloy MJ, Wood E, Grebely J. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug Alcohol Depend. 2015;152:272-6. Impact factor 3.4; Citations 0)
7. Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJ, Wood E, Montaner JS. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29(8):965-73. (Impact factor 6.6; Citations 1)
8. Nosyk B, Lima V, Colley G, Yip B, Hogg RS, Montaner JS. Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. Pharmacoeconomics. 2015;33(3):243-53. (Impact factor 3.3; Citations 0)
9. Liu JC, Leung JM, Ngan DA, Nashta NF, Guillemi S, Harris M, Lima VD, Um SJ, Li Y, Tam S, Shaipanich T, Raju R, Hague C, Leipsic JA, Bourbeau J, Tan WC, Harrigan PR, Sin DD, Montaner J, Man SF. Absolute Leukocyte Telomere Length in HIV-Infected and Uninfected Individuals: Evidence of Accelerated Cell Senescence in HIV-Associated Chronic Obstructive Pulmonary Disease. PLoS One. 2015;10(4):e0124426. (Impact factor 3.5; Citations 0)
10. Lourenço L, Samji H, Nohpal A, Chau W, Colley G, Lepik K, Barrios R, Lima V, Hogg R, Montaner J, Kesselring S, Moore D. Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada. HIV Med. 2015. [Epub ahead of print] (Impact factor 3.5; Citations 0)
11. Patterson S, Cescon A, Samji H, Cui Z, Yip B, Lepik KJ, Moore D, Lima VD, Nosyk B, Harrigan PR, Montaner JS, Shannon K, Wood E, Hogg RS. Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort. Int J Epidemiol. 2015;44(1):58-67. (Impact factor 9.2; Citations 1)
12. Samji H, Taha T, Moore D, Burchell A, Cescon A, Cooper C, Raboud J, Klein M, Loutfy M, Machouf N, Tsoukas C, Montaner J, Hogg R; Canadian Observational Cohort (CANOC) Collaboration; Canadian Observational Cohort CANOC Collaboration. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med. 2015;16(2):76-87. (Impact factor 3.5; Citations 1)

Areas of special interest

• Biostatistics

• Epidemiological Methods

• Epidemiology of HIV Disease

• Epidemiology of HCV Disease

• Public Health

* Health care utilization

• Mathematical Modeling of Infectious Diseases